Eman El-Khateeb

@tanta.edu.eg

Clinical Pharmacy Department/ Faculty of Pharmacy
Faculty of Pharmacy- Tanta University/ Lecturer of Clinical Pharmacy

Eman El-Khateeb


         Download Compact PDF  
https://researchid.co/eelkhateeb

EDUCATION

BSc in Pharmacy and Pharmaceutical Scirnces 2007- Tanta University- Egypt
MSc in Clinical Pharmacy 2015- Tanta University- Egypt
PhD in Pharmacy and Pharmaceutical Sciences 2021- University of Manchester- UK

RESEARCH, TEACHING, or OTHER INTERESTS

Hepatology, Modeling and Simulation, Pharmaceutical Science, Pharmacology
655

Scholar Citations

14

Scholar h-index

17

Scholar i10-index

RECENT SCHOLAR PUBLICATIONS

  • Model-Informed Precision Dosing Strategy for Sitagliptin and Duloxetine in Hepatic Cirrhosis: An Interventional Pilot Study
    A Fouda, NM EL-Khodary, AA Amin, MHA Hussien, K Abdelkawy, ...
    2026
  • Physiologically based pharmacokinetic modeling for optimal dosage prediction of statins and warfarin in patients with liver cirrhosis
    N Galal, NM El-Khodary, MHA Hussien, K Abdelkawy, E El-Khateeb
    European Journal of Clinical Pharmacology 82 (4), 106 , 2026
    2026
  • Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis
    HA AlRasheed, MS Abdallah, EM Mosalam, MM Bahaa, MM Salahuddin, ...
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1-18 , 2026
    2026
  • Evaluating alterations in drug-metabolizing enzymes in cancer: insights from in vivo, in vitro, and biomarker studies
    E El-Khateeb, O Hatley, I Gardner, U Ezuruike, F Stader
    Drug Metabolism and Disposition, 100279 , 2026
    2026
  • Using Physiologically Based Pharmacokinetic Modeling and Simulations to Predict Antihypertensive Drug Doses in Cirrhotic Patients
    M Tarek, AA Ali, R Biomy, K Abdelkawy, E El‐Khateeb
    The Journal of Clinical Pharmacology 66 (1), e70148 , 2026
    2026
  • A randomized controlled pilot study evaluating the safety and efficacy of nifuroxazide in patients with ulcerative colitis
    HA AlRasheed, MS Abdallah, E El-Khateeb, M Kamal, S Alrubia, ...
    Drug Design, Development and Therapy, 5539-5552 , 2025
    2025
    Citations: 7
  • Therapeutic Modulation of IL‐6/STAT‐3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study
    KM Aldossary, MS Abdallah, N Kamal, MM Bahgat, S Alrubia, ...
    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 45 (12 … , 2025
    2025
    Citations: 1
  • Concentration-dependent blood binding: assessing implications through physiologically based Pharmacokinetic modeling of tacrolimus as a case example
    E El-Khateeb, D Karsanji, AS Darwich, A Rostami-Hodjegan
    Journal of Pharmacokinetics and Pharmacodynamics 52 (5), 50 , 2025
    2025
  • Development and Verification of Virtual Population Models for Predicting Drug Pharmacokinetics in Ethnic North American Populations
    U Ezuruike, J Dinh, E El‐Khateeb, A Blenkinsop, O Hatley, I Gardner
    CPT: Pharmacometrics & Systems Pharmacology 14 (10), 1598-1615 , 2025
    2025
    Citations: 1
  • Colo‐protective effects of pentoxifylline alone or in combination with mesalamine in colitis through Sphingosine Kinase 1/Sphingosine 1 phosphate, and Zonula Occuldin 1 …
    FA Alherz, MS Abdallah, EM Mosalam, MM Bahaa, TA Elmasry, ...
    Pharmacology Research & Perspectives 13 (3), e70115 , 2025
    2025
    Citations: 4
  • Interplay of oxidative stress and Inflammasome activation and clinical indices in Parkinson’s disease: insights from serum SIRT1, Nrf2, and NLRP3 levels and PDQ-39—a cross …
    KM Aldossary, E Hamza, MM Kamel, AS Alsegiani, S Alrubia, WS Sarawi, ...
    Frontiers in Neuroscience 19, 1738871 , 2025
    2025
  • Fenofibrate as an adjunct therapy for ulcerative colitis: targeting inflammation via SIRT1, NLRP3, and AMPK pathways: a randomized controlled pilot study
    SJ Alarfaj, MM Bahaa, TA Elmasry, EI Elberri, E El-Khateeb, AO Hamouda, ...
    Drug Design, Development and Therapy, 5239-5253 , 2024
    2024
    Citations: 13
  • Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval—A Case Study Using Levonorgestrel
    S Cole, H Pertinez, AS Butler, E Kerwash, S Bhat, E El-Khateeb, A Owen
    Pharmaceuticals 17 (12), 1640 , 2024
    2024
  • A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator
    L Curry, S Alrubia, FY Bois, R Clayton, E El-Khateeb, TN Johnson, ...
    CPT Pharmacometrics Syst Pharmacol, 1-19 , 2024
    2024
    Citations: 14
  • Correlation between depression scores and serum NF‐ĸB/NLRP3 axis, biotinidase, and HMGB1 after treatment with isotretinoin in patients with acne vulgaris
    AY Binsaleh, LS Ali, MM Bahaa, TA Elmasry, WA Negm, AO Hamouda, ...
    Journal of Cosmetic Dermatology, 1-9 , 2024
    2024
    Citations: 1
  • Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models
    H Pertinez, A Kaushik, P Curley, U Arshad, E El-Khateeb, SY Li, ...
    bioRxiv , 2024
    2024
    Citations: 2
  • Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver
    AM Vasilogianni, S Alrubia, E El-Khateeb, ZM Al-Majdoub, N Couto, ...
    Molecular Omics 20 (2), 115-127 , 2024
    2024
    Citations: 3
  • A Randomized Controlled Trial Comparing Tacrolimus versus Hydrocortisone for the Treatment of Atopic Dermatitis in Children: New Perspectives on Interferon Gamma-Induced …
    M Bahaa, AY Binsaleh, TA Elmasry, EI Elberri, FA Kotkata, E El-Khateeb, ...
    Frontiers in Medicine 11, 1399305 , 2024
    2024
    Citations: 5
  • The potential therapeutic effect of metformin in type 2 diabetic patients with severe COVID-19.
    HM Al-Kuraishy, AI Al-Gareeb, AA El Kholy, E El-Khateeb, A Alexiou, ...
    European Review for Medical & Pharmacological Sciences 27 (23) , 2023
    2023
    Citations: 18
  • Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease
    E El-Khateeb, R Chinnadurai, J Al Qassabi, D Scotcher, AS Darwich, ...
    Therapeutic Drug Monitoring 45 (6), 743-753 , 2023
    2023
    Citations: 4

MOST CITED SCHOLAR PUBLICATIONS

  • Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platforms
    E El‐Khateeb, S Burkhill, S Murby, H Amirat, A Rostami‐Hodjegan, ...
    Biopharmaceutics & Drug Disposition 42 (4), 107-117 , 2021
    2021
    Citations: 143
  • Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment
    E El-Khateeb, B Achour, ZM Al-Majdoub, J Barber, A Rostami-Hodjegan
    Molecular Pharmaceutics 18 (9), 3563-3577 , 2021
    2021
    Citations: 84
  • time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment
    E El‐Khateeb, AS Darwich, B Achour, V Athwal, A Rostami‐Hodjegan
    Alimentary pharmacology & therapeutics 54 (4), 388-401 , 2021
    2021
    Citations: 70
  • Mass Spectrometry‐Based Abundance Atlas of ABC Transporters in Human Liver, Gut, Kidney, Brain, and Skin
    JB Zubida M. Al‐Majdoub, Brahim Achour, Narciso Couto, Martyn Howard ...
    FEBS letters , 2020
    2020
    Citations: 42
  • Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats
    A El-Sisi, S Hegazy, E El-Khateeb
    PPAR research 2013 (1), 781348 , 2013
    2013
    Citations: 39
  • Pharmacokinetics under the COVID‐19 storm
    V Pilla Reddy, E El‐Khateeb, H Jo, N Giovino, E Lythgoe, S Sharma, ...
    British Journal of Clinical Pharmacology 89 (1), 158-186 , 2020
    2020
    Citations: 35
  • Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: applications in translational pharmacology and recommendations for best practice
    E El-Khateeb, AM Vasilogianni, S Alrubia, ZM Al-Majdoub, N Couto, ...
    Pharmacology & Therapeutics 203, 107397 , 2019
    2019
    Citations: 34
  • Proteomic quantification of changes in abundance of drug-metabolizing enzymes and drug transporters in human liver cirrhosis: different methods, similar outcomes
    E El-Khateeb, ZM Al-Majdoub, A Rostami-Hodjegan, J Barber, B Achour
    Drug Metabolism and Disposition 49 (8), 610-618 , 2021
    2021
    Citations: 33
  • Scaling factors for clearance in adult liver cirrhosis
    E El-Khateeb, B Achour, D Scotcher, ZM Al-Majdoub, V Athwal, J Barber, ...
    Drug Metabolism and Disposition 48 (12), 1271-1282 , 2020
    2020
    Citations: 24
  • The potential therapeutic effect of metformin in type 2 diabetic patients with severe COVID-19.
    HM Al-Kuraishy, AI Al-Gareeb, AA El Kholy, E El-Khateeb, A Alexiou, ...
    European Review for Medical & Pharmacological Sciences 27 (23) , 2023
    2023
    Citations: 18
  • A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new …
    SJ Alarfaj, MM Bahaa, HA Yassin, E El-Khateeb, FA Kotkata, ...
    European Review for Medical & Pharmacological Sciences 27 (16) , 2023
    2023
    Citations: 18
  • Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease
    AM Vasilogianni, E El-Khateeb, ZM Al-Majdoub, S Alrubia, ...
    Journal of proteomics 263, 104601 , 2022
    2022
    Citations: 18
  • Bioanalytical strategies in drug discovery and development
    A Thakur, Z Tan, T Kameyama, E El-Khateeb, S Nagpal, S Malone, ...
    Drug Metabolism Reviews 53 (3), 434-458 , 2021
    2021
    Citations: 18
  • A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator
    L Curry, S Alrubia, FY Bois, R Clayton, E El-Khateeb, TN Johnson, ...
    CPT Pharmacometrics Syst Pharmacol, 1-19 , 2024
    2024
    Citations: 14
  • Fenofibrate as an adjunct therapy for ulcerative colitis: targeting inflammation via SIRT1, NLRP3, and AMPK pathways: a randomized controlled pilot study
    SJ Alarfaj, MM Bahaa, TA Elmasry, EI Elberri, E El-Khateeb, AO Hamouda, ...
    Drug Design, Development and Therapy, 5239-5253 , 2024
    2024
    Citations: 13
  • Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind …
    E El-Khateeb, EI El-Berri, EM Mosalam, MZ Nooh, S Abdelsattar, ...
    Frontiers in Pharmacology 14, 1153653 , 2023
    2023
    Citations: 11
  • A family of QconCATs (Quantification conCATemers) for the quantification of human pharmacological target proteins
    AM Vasilogianni, E El-Khateeb, B Achour, S Alrubia, A Rostami-Hodjegan, ...
    Journal of proteomics 261, 104572 , 2022
    2022
    Citations: 11
  • A randomized controlled pilot study evaluating the safety and efficacy of nifuroxazide in patients with ulcerative colitis
    HA AlRasheed, MS Abdallah, E El-Khateeb, M Kamal, S Alrubia, ...
    Drug Design, Development and Therapy, 5539-5552 , 2025
    2025
    Citations: 7
  • A Randomized Controlled Trial Comparing Tacrolimus versus Hydrocortisone for the Treatment of Atopic Dermatitis in Children: New Perspectives on Interferon Gamma-Induced …
    M Bahaa, AY Binsaleh, TA Elmasry, EI Elberri, FA Kotkata, E El-Khateeb, ...
    Frontiers in Medicine 11, 1399305 , 2024
    2024
    Citations: 5
  • Colo‐protective effects of pentoxifylline alone or in combination with mesalamine in colitis through Sphingosine Kinase 1/Sphingosine 1 phosphate, and Zonula Occuldin 1 …
    FA Alherz, MS Abdallah, EM Mosalam, MM Bahaa, TA Elmasry, ...
    Pharmacology Research & Perspectives 13 (3), e70115 , 2025
    2025
    Citations: 4